<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BUDESONIDE- budesonide capsule </strong><br>Carilion Materials Management<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use safely and effectively.  See full prescribing information for .   Initial U.S. Approval: 1997
        <span class="Bold">budesonide capsules (enteric coated)</span><span class="Bold">budesonide capsules (enteric coated)</span><br><br><span class="Bold">BUDESONIDE capsules (enteric coated), for oral use</span><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Budesonide capsules (enteric coated) are a glucocorticosteroid indicated for: </p>
<dl>
<dt>•</dt>
<dd>Treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon. ( )
                                        <a href="#ID_a0185723-670f-46ab-9b8a-3b9644c2e7c0">1.1</a>
</dd>
<dt>•</dt>
<dd>Maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months. ( )
                                        <a href="#ID_eb46640b-9930-4d04-a2d2-6128dc2609bb">1.2</a>
</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Mild to moderate active Crohn’s disease: 9 mg once daily in the morning for up to 8 weeks. Repeated 8 week courses of budesonide capsules (enteric coated) can be given for recurring episodes of active disease. ( )
                                        <span class="Bold"></span><a href="#ID_5532e391-8353-41a8-98d1-a5995290ad27">2.1</a>
</dd>
<dt>•</dt>
<dd>Maintenance of clinical remission of mild to moderate Crohn’s disease: 6 mg once daily for up to 3 months. Continued treatment with budesonide capsules (enteric coated) 6 mg for more than 3 months has not been shown to provide substantial clinical benefit. ( )
                                        <a href="#ID_3fcaf3a0-5d5b-409a-947e-b710c96be87c">2.2</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Capsules: 3 mg ( )
                                    <a href="#ID_d963dea7-7e33-4aa3-bf36-8b1ba73b3e5a">3</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the ingredients in budesonide capsules (enteric coated). ( )
                                    <a href="#ID_bfb195d3-d9e8-475a-9e39-de1c4a58191f">4</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Since budesonide capsules (enteric coated) are a glucocorticosteroid, general warnings concerning glucocorticoids should be followed. ( )
                                        <span class="Underline">Hypercorticism and adrenal suppression:</span><a href="#ID_ebcddafe-38b0-4f25-b37d-eb96b86d81cc">5.1</a>
</dd>
<dt>•</dt>
<dd>Care is needed in patients who are transferred from glucocorticosteroid treatment with high systemic effects to corticosteroids with lower systemic availability, such as budesonide capsules (enteric coated). ( )
                                        <span class="Underline">Transferring patients from systemic glucocorticosteroid therapy:</span><a href="#ID_c73ecdc3-be45-4c39-82d0-2620835785b0">5.2</a>
</dd>
<dt>•</dt>
<dd>Potential worsening of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (e.g., existing <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, fungal, bacterial, viral, or parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>). Use with caution in patients with these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. More serious or even fatal course of <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">chickenpox</span> or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can occur in susceptible patients. ( )
                                        <span class="Underline"><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span>:</span><a href="#ID_379c624d-3894-486e-8301-31cf2e6028ce">5.3</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥ 5%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. ( )
                                    <a href="#ID_f8beb5c5-fcc7-417f-a692-daf8942232b5">6.1</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact</span><span class="Bold">Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX)</span><span class="Bold">or FDA at 1-800-FDA-1088 or</span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Cytochrome P450 3A4 inhibitors (e.g., ketoconazole, grapefruit juice) should be avoided. May cause increased systemic corticosteroid effects. ( , , )
                                        <a href="#ID_febfe84e-26ee-4728-82ed-ede44e034b92">2.3</a><a href="#ID_2f34ddac-35bd-4586-a9e0-d642b0993690">7</a><a href="#ID_cb451699-af19-4691-a06b-a5ff3321acfb">12.3</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>: Monitor patients for signs and/or symptoms of hypercorticism. ( , )
                                        <a href="#ID_2edf6464-c355-49d6-bd95-bd11e518b799">5.4</a><a href="#ID_fce2707e-4b9d-4949-849f-3be4cc5994f1">8.6</a>
</dd>
</dl></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Mild to Moderate Active Crohn’s Disease</a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Mild to Moderate Active Crohn’s Disease</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease</a></h2>
<h2><a href="#section-2.3" class="toc">2.3	CYP3A4 inhibitors</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Hypercorticism and Adrenal Suppression</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Transferring Patients from Systemic Glucocorticosteroid Therapy</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Increased Systemic Glucocorticosteroid Susceptibility</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Other Glucocorticosteroid Effects</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6	<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Hypercorticism and Adrenal Suppression</a></h2>
<h2><a href="#section-15.2" class="toc">17.2	<span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3	How to Take Budesonide Capsules (enteric coated)</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_4cca3c58-4ba2-4856-aeff-29e3231170c9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a0185723-670f-46ab-9b8a-3b9644c2e7c0"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Mild to Moderate Active Crohn’s Disease</h2>
<p class="First">Budesonide capsules (enteric coated) are indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_eb46640b-9930-4d04-a2d2-6128dc2609bb"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease</h2>
<p class="First">Budesonide capsules (enteric coated) are indicated for the maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_68102ed7-2efe-4d08-a4d4-f4474b6a59f8"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5532e391-8353-41a8-98d1-a5995290ad27"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Mild to Moderate Active Crohn’s Disease</h2>
<p class="First">The recommended adult dosage for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon is 9 mg orally taken once daily in the morning for up to 8 weeks. Repeated 8 week courses of budesonide capsules (enteric coated) can be given for recurring episodes of active disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3fcaf3a0-5d5b-409a-947e-b710c96be87c"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease</h2>
<p class="First">Following an 8 week course(s) of treatment for active disease and once the patient’s symptoms are controlled (CDAI less than 150), budesonide capsules (enteric coated) 6 mg orally is recommended once daily for maintenance of clinical remission up to 3 months. If symptom control is still maintained at 3 months an attempt to taper to complete cessation is recommended. Continued treatment with budesonide capsules (enteric coated) 6 mg for more than 3 months has not been shown to provide substantial clinical benefit.</p>
<p>Patients with mild to moderate active Crohn’s disease involving the ileum and/or ascending colon have been switched from oral prednisolone to budesonide capsules (enteric coated) with no reported episodes of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. Since prednisolone should not be stopped abruptly, tapering should begin concomitantly with initiating budesonide capsule (enteric coated) treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_febfe84e-26ee-4728-82ed-ede44e034b92"></a><a name="section-2.3"></a><p></p>
<h2>2.3	CYP3A4 inhibitors</h2>
<p class="First">If concomitant administration with ketoconazole, or any other CYP3A4 inhibitor, is indicated, patients should be closely monitored for increased signs and/or symptoms of hypercorticism. Grapefruit juice, which is known to inhibit CYP3A4, should also be avoided when taking budesonide capsules (enteric coated). In these cases, reduction in the dose of budesonide capsules (enteric coated) should be considered [ ].
                                    <span class="Italics">see and
                                        <a href="#ID_2f34ddac-35bd-4586-a9e0-d642b0993690">Drug Interactions (7)</a><a href="#ID_cb451699-af19-4691-a06b-a5ff3321acfb">Clinical Pharmacology (12.3)</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_d963dea7-7e33-4aa3-bf36-8b1ba73b3e5a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Budesonide capsules (enteric coated) 3 mg have a red opaque cap and red opaque body, hard shell gelatin capsule filled with white to off-white enteric-coated pellets with no markings. The capsules are axially printed with over in black ink on both the cap and body.
                            <span class="Bold">MYLAN</span><span class="Bold">7155</span></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_bfb195d3-d9e8-475a-9e39-de1c4a58191f"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Budesonide capsules (enteric coated) are contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to budesonide or any of the ingredients of budesonide capsules (enteric coated). <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have occurred [ ].
                            <span class="Italics">see
                                <a href="#ID_72f50acc-6199-4796-84ea-433cd80909c0">Adverse Reactions (6.2)</a></span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_3956ebf8-3eb4-4dbc-ae09-9fff13c12cf7"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ebcddafe-38b0-4f25-b37d-eb96b86d81cc"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Hypercorticism and Adrenal Suppression</h2>
<p class="First">When glucocorticosteroids are used chronically, systemic effects such as hypercorticism and adrenal suppression may occur. Glucocorticosteroids can reduce the response of the hypothalamus-pituitary-adrenal (HPA) axis to stress. In situations where patients are subject to surgery or other stress situations, supplementation with a systemic glucocorticosteroid is recommended. Since budesonide capsules (enteric coated) are a glucocorticosteroid, general warnings concerning glucocorticoids should be followed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c73ecdc3-be45-4c39-82d0-2620835785b0"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Transferring Patients from Systemic Glucocorticosteroid Therapy</h2>
<p class="First">Care is needed in patients who are transferred from glucocorticosteroid treatment with high systemic effects to corticosteroids with lower systemic availability, such as budesonide capsules (enteric coated), since symptoms attributed to withdrawal of steroid therapy, including those of acute adrenal suppression or <span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">benign intracranial hypertension</span>, may develop. Adrenocortical function monitoring may be required in these patients and the dose of glucocorticosteroid treatment with high systemic effects should be reduced cautiously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_379c624d-3894-486e-8301-31cf2e6028ce"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Patients who are on drugs that suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> than healthy individuals. Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in susceptible patients or patients on immunosuppressant doses of glucocorticosteroids. In patients who have not had these diseases, particular care should be taken to avoid exposure.</p>
<p>How the dose, route and duration of glucocorticosteroid administration affect the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease and/or prior glucocorticosteroid treatment to the risk is also not known. If exposed, therapy with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See prescribing information for VZIG and IG.) If chicken pox develops, treatment with antiviral agents may be considered.</p>
<p>Glucocorticosteroids should be used with caution, if at all, in patients with active or quiescent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, untreated fungal, bacterial, systemic viral or parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Replacement of systemic glucocorticosteroids with budesonide capsules (enteric coated) may unmask allergies (e.g., <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> and <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>), which were previously controlled by the systemic drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2edf6464-c355-49d6-bd95-bd11e518b799"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Increased Systemic Glucocorticosteroid Susceptibility</h2>
<p class="First">Reduced liver function affects the elimination of glucocorticosteroids, and increased systemic availability of oral budesonide has been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span> [ ].
                                    <span class="Italics">see
                                        <a href="#ID_fce2707e-4b9d-4949-849f-3be4cc5994f1">Use in Specific Populations (8.6)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7fe95e2e-0f6d-4c56-ae1f-e36a451556d2"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Other Glucocorticosteroid Effects</h2>
<p class="First">Caution should be taken in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, or with a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, or with any other condition where glucocorticosteroids may have unwanted effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_e50a73cd-ee3c-459e-9972-2e66e283389d"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Systemic glucocorticosteroid use may result in the following:</p>
<dl>
<dt>•</dt>
<dd>Hypercorticism and Adrenal Suppression [ ]
                                <span class="Italics">see
                                    <a href="#ID_ebcddafe-38b0-4f25-b37d-eb96b86d81cc">Warnings and Precautions (5.1)</a></span>
</dd>
<dt>•</dt>
<dd>Symptoms of steroid withdrawal in those patients transferring from Systemic Glucocorticosteroid Therapy [ ]
                                <span class="Italics">see
                                    <a href="#ID_c73ecdc3-be45-4c39-82d0-2620835785b0">Warnings and Precautions (5.2)</a></span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span> [ ]
                                <span class="Italics">see
                                    <a href="#ID_379c624d-3894-486e-8301-31cf2e6028ce">Warnings and Precautions (5.3)</a></span>
</dd>
<dt>•</dt>
<dd>Increased Systemic Glucocorticosteroid Susceptibilty [ ]
                                <span class="Italics">see
                                    <a href="#ID_2edf6464-c355-49d6-bd95-bd11e518b799">Warnings and Precautions (5.4)</a></span>
</dd>
<dt>•</dt>
<dd>Other Glucocorticosteroid Effects [ ]
                                <span class="Italics">see
                                    <a href="#ID_7fe95e2e-0f6d-4c56-ae1f-e36a451556d2">Warnings and Precautions (5.5)</a></span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f8beb5c5-fcc7-417f-a692-daf8942232b5"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p></p>
<p>The safety of budesonide capsules (enteric coated) was evaluated in 651 patients in five short-term, active disease state studies. They ranged in age from 17 to 74 (mean 35), 40% were male and 97% were white, 2.6% were greater than or equal to 65 years of age. Five hundred and twenty patients were treated with budesonide capsules (enteric coated) 9 mg (total daily dose). The most common adverse reactions reported were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and symptoms of hypercorticism. Clinical studies have shown that the frequency of glucocorticosteroid-associated adverse reactions was substantially reduced with budesonide capsules (enteric coated) compared with prednisolone at therapeutically equivalent doses. Adverse reactions occurring in greater than or equal to 5% of the patients are listed in Table 1:</p>
<table>
<caption><span>Table 1. Adverse Reactions Occurring in Greater Than or Equal to 5% of the Patients in Any Treated Group</span></caption>
<col width="24%">
<col width="21%">
<col width="19%">
<col width="19%">
<col width="17%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>This drug is not approved for the treatment of Crohn’s disease in the United States.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Budesonide Capsules (Enteric Coated)</span></p>
<p><span class="Bold">9 mg</span></p>
<p><span class="Bold">n = 520</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">n = 107</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Prednisolone</span></p>
<p><span class="Bold">40 mg</span></p>
<p><span class="Bold">n = 145</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p>
<p><span class="Bold">n = 88</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">107(21)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19(18)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31(21)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11(13)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">Respiratory Infection</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">55(11)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7(7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">20(14)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">57(11)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10(9)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18(12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">7(8)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">36(7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10(9)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17(12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">31(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4(4)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17(12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3(3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">38(7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18(12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">32(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">18(17)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(4)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10(11)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12(8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">29(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(4)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">25(5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8(7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11(8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0(0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">24(5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">8(7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17(12)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2(2)</p></td>
</tr>
</tbody>
</table>
<p>The safety of budesonide capsules (enteric coated) was evaluated in 233 patients in four long-term clinical trials (52 weeks). A total of 145 patients were treated with budesonide capsules (enteric coated) 6 mg. A total of 8% of budesonide capsule (enteric coated) patients discontinued treatment due to adverse reactions compared with 10% in the placebo group. The adverse reaction profile in long-term treatment of Crohn’s disease was similar to that of short-term treatment with budesonide capsules (enteric coated) 9 mg in active Crohn’s disease.</p>
<p>In the long-term clinical trials, the following adverse reactions occurred in greater than or equal to 5% of the 6 mg budesonide capsule (enteric coated) patients and are not listed in (Table 1) or by body system below: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (10%); <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> (8%); <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">infection viral</span> (6%); and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (5%).</p>
<p>Adverse reactions, occurring in patients treated with budesonide capsules (enteric coated) 9 mg (total daily dose) in short-term active disease state studies and/or budesonide capsules (enteric coated) 6 mg (total daily dose) long-term, with an incidence less than 5% and greater than placebo are listed below by system organ class:</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>
                                        <span class="Italics">Blood and lymphatic system disorders:
                                            <span class="Bold"></span></span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye abnormality</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, flu-like disorder, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
                                        <span class="Italics">General disorders and administration site conditions:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4145825" conceptname="Anorectal disorder">anus disorder</span>, Crohn’s disease aggravated, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="4295370" conceptname="Gastrointestinal fistula">gastrointestinal fistula</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>, <span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">tooth disorder</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear infection</span>-not otherwise specified, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">thrush</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>:</span>
</dd>
<dt> </dt>
<dd>c-reactive protein increased, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>
                                        <span class="Italics">Investigations:</span>
</dd>
<dt> </dt>
<dd>appetite increased, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>
                                        <span class="Italics">Metabolism and nutrition disorders:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>
                                        <span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, parasthesia, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>
                                        <span class="Italics">Psychiatric disorders:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, micturition frequency, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>
                                        <span class="Italics">Renal and urinary disorders:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">intermenstrual bleeding</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>
                                        <span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pharynx disorder
                                        <span class="Italics">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>
                                        <span class="Italics">Skin and subcutaneous tissue disorders:</span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span>
</dd>
</dl>
<p>Table 2 displays the frequency and incidence of signs/symptoms of hypercorticism by active questioning of patients in short-term clinical trials.</p>
<table>
<caption><span>Table 2. Summary and Incidence of Signs/Symptoms of Hypercorticism in Short-Term Studies</span></caption>
<col width="20%">
<col width="21%">
<col width="17%">
<col width="17%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Statistically significantly different from budesonide capsules (enteric coated) 9 mg.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Adverse reaction dictionary included term <span class="product-label-link" type="condition" conceptid="4309771" conceptname="Abnormal hair growth">hair growth increased</span>, local and <span class="product-label-link" type="condition" conceptid="4309771" conceptname="Abnormal hair growth">hair growth increased</span>, general.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Budesonide Capsules (Enteric Coated)</span></p>
<p><span class="Bold">9 mg</span></p>
<p><span class="Bold">n = 427</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">n = 107</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Prednisolone</span></p>
<p><span class="Bold">Taper 40 mg
                                                        <br></span></p>
<p><span class="Bold">n = 145</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Signs/Symptom</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">63(15)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14(13)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">33(23)
                                                    <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span> Easily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">63(15)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12(11)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13(9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Moon Face</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">46(11)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4(4)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">53(37)
                                                    <a href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">Swollen Ankles</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">32(7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(6)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">13(9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span>
                                                    <a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">22(5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2(2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">Buffalo Hump</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2(2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">Skin Striae</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4(1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2(2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0(0)</p></td>
</tr>
</tbody>
</table>
<p>Table 3 displays the frequency and incidence of signs/symptoms of hypercorticism by active questioning of patients in long-term clinical trials.</p>
<table>
<caption><span>Table 3. Summary and Incidence of Symptoms of Hypercorticism in Long-Term Studies</span></caption>
<col width="22%">
<col width="21%">
<col width="21%">
<col width="19%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Budesonide Capsules (Enteric Coated)</span></p>
<p><span class="Bold">3 mg</span></p>
<p><span class="Bold">n = 88</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Budesonide Capsules (Enteric Coated)</span></p>
<p><span class="Bold">6 mg</span></p>
<p><span class="Bold">n = 145</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">n = 143</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="Bold">Signs/Symptom</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Number (%)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Bruising</span> Easily</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4(5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">15(10)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">4(5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">14(10)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3(2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Moon Face</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3 (3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">6(4)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">5(3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1(1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">Swollen Ankles</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3(2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">3(2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">Buffalo Hump</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">1 (1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">Skin Striae</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">2 (2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p>The incidence of signs/symptoms of hypercorticism as described above in long-term clinical trials was similar to that seen in the short-term clinical trials.</p>
<p>A randomized, open, parallel-group multicenter safety study specifically compared the effect of budesonide capsules (enteric coated) (less than 9 mg per day) and prednisolone (less than 40 mg per day) on bone mineral density over 2 years when used at doses adjusted to disease severity. Bone mineral density decreased significantly less with budesonide capsules (enteric coated) than with prednisolone in steroid-naïve patients, whereas no difference could be detected between treatment groups for steroid-dependent patients and previous steroid users. The incidence of symptoms associated with hypercorticism was significantly higher with prednisolone treatment.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0262525d-80d2-4122-aa88-6eb9e44a8848"></a><a name="section-6.1.1"></a><p></p>
<h3>Clinical Laboratory Test Findings</h3>
<p class="First">The following potentially clinically significant laboratory changes in clinical trials, irrespective of relationship to budesonide capsules (enteric coated), were reported in greater than or equal to 1% of patients: <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">pyuria</span>, <span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">erythrocyte sedimentation rate increased</span>, alkaline phosphatase increased, atypical <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, C-reactive protein increased, and <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_72f50acc-6199-4796-84ea-433cd80909c0"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported during post-approval use of budesonide capsules (enteric coated). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<dl>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:
                                            <span class="Bold"></span></span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">Benign intracranial hypertension</span>
                                        <span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:
                                            <span class="Bold"></span></span>
</dd>
<dt> </dt>
<dd><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Mood swings</span>
                                        <span class="Italics">Psychiatric Disorders:
                                            <span class="Bold"></span></span>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_2f34ddac-35bd-4586-a9e0-d642b0993690"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an 8-fold increase of the systemic exposure to oral budesonide. If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered. After extensive intake of grapefruit juice (which inhibits CYP3A4 activity predominantly in the intestinal mucosa), the systemic exposure for oral budesonide increased about two times. Ingestion of grapefruit or grapefruit juice should be avoided in connection with budesonide administration [ ].
                            <span class="Italics">see
                                <a href="#ID_cb451699-af19-4691-a06b-a5ff3321acfb">Clinical Pharmacology (12.3)</a></span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_993a8d6b-7db3-4b53-8d14-25b642c6bb0c"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_55b5d183-207e-4420-9c61-118639f2ed03"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_c1b18206-920d-47e2-8d9c-c4c817a368b3"></a><a name="section-8.1.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category C</h3>
<p class="First">Budesonide was teratogenic and embryocidal in rabbits and rats. Budesonide produced fetal loss, decreased pup weights, and skeletal abnormalities at subcutaneous doses of 25 mcg/kg in rabbits (approximately 0.05 times the maximum recommended human dose on a body surface area basis) and 500 mcg/kg in rats (approximately 0.5 times the maximum recommended human dose on a body surface area basis).</p>
<p>There are no adequate and well-controlled studies in pregnant women. Budesonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="ID_c62c511d-f454-4739-a51a-28ce8fc03d4d"></a><a name="section-8.1.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Hypoadrenalism</span> may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_11415992-4a31-4aff-8fab-8a920a5219f7"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The disposition of budesonide when delivered by inhalation from a dry powder inhaler at doses of 200 or 400 mcg twice daily for at least 3 months was studied in eight lactating women with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> from 1 to 6 months postpartum . Systemic exposure to budesonide in these women appears to be comparable to that in non-lactating women with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> from other studies. Breast milk obtained over eight hours post-dose revealed that the maximum budesonide concentration for the 400 and 800 mcg total daily doses was 0.39 and 0.78 nmol/L, respectively, and occurred within 45 minutes after inhalation. The estimated oral daily dose of budesonide from breast milk to the infant is approximately 0.007 and 0.014 mcg/kg per day for the two dose regimens used in this study, which represents approximately 0.3% to 1% of the dose inhaled by the mother. Budesonide plasma concentrations obtained from five infants at about 90 minutes after breast feeding (and about 140 minutes after drug administration to the mother) were below quantifiable levels (less than 0.02 nmol/L in four infants and less than 0.04 nmol/L in one infant).
                                    <span class="Sup">1</span></p>
<p>The recommended daily dose of budesonide capsules (enteric coated) is higher (up to 9 mg daily) compared with inhaled budesonide (up to 800 mg daily) given to mothers in the above study. The maximum budesonide plasma concentration following a 9 mg daily dose (in both single- and repeated-dose pharmacokinetic studies) of oral budesonide is approximately 5 to 10 nmol/L which is up to 10 times higher than the 1 to 2 nmol/L for a 800 mg daily dose of inhaled budesonide at steady state in the above inhalation study.</p>
<p>Since there are no data from controlled trials on the use of budesonide capsules (enteric coated) by nursing mothers or their infants, and because of the potential for serious adverse reactions in nursing infants from budesonide capsules (enteric coated), a decision should be made whether to discontinue nursing or to discontinue budesonide capsules (enteric coated), taking into account the clinical importance of budesonide capsules (enteric coated) to the mother.</p>
<p>Budesonide is secreted in human milk. Data from budesonide delivered via dry powder inhaler indicates that the total daily oral dose of budesonide available in breast milk to the infant is approximately 0.3% to 1% of the dose inhaled by the mother. Assuming the coefficient of extrapolation between the inhaled and oral doses is constant across all dose levels, at therapeutic doses of budesonide capsules (enteric coated), budesonide exposure to the nursing child may be up to 10 times higher than that by budesonide inhalation.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_18979810-5a91-4d16-888c-64d81333741b"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. Systemic and inhaled corticosteroids, including budesonide capsules (enteric coated), may cause a reduction of growth velocity in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_c9365781-e5b1-4399-9e91-c4a3ab0605b4"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of budesonide capsules (enteric coated) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fce2707e-4b9d-4949-849f-3be4cc5994f1"></a><a name="section-8.5"></a><p></p>
<h2>8.6	<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h2>
<p class="First">Patients with moderate to severe liver disease should be monitored for increased signs and/or symptoms of hypercorticism. Reducing the dose of budesonide capsules (enteric coated) should be considered in these patients [ ].
                                    <span class="Italics">see
                                        <a href="#ID_2edf6464-c355-49d6-bd95-bd11e518b799">Warnings and Precautions (5.4)</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_84f6a441-7b6d-4416-9073-6d941fd71f49"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Reports of acute toxicity and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> following overdosage of glucocorticosteroids are rare. Treatment consists of immediate gastric lavage or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> followed by supportive and symptomatic therapy.</p>
<p>If glucocorticosteroids are used at excessive doses for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span>, systemic glucocorticosteroid effects such as hypercorticism and adrenal suppression may occur. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage may be reduced temporarily.</p>
<p>Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span> and <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_7dfdefd6-6d32-4486-9a2e-1fb3f5b92c7c"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Budesonide the active ingredient of budesonide capsules (enteric coated), is a synthetic corticosteroid. Budesonide is designated chemically as (RS)-11β, 16α, 17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde. Budesonide is provided as a mixture of two epimers (22R and 22S). The molecular formula of budesonide is C H O and its molecular weight is 430.5. Its structural formula is:
                            <span class="Sub">25</span><span class="Sub">34</span><span class="Sub">6</span></p>
<div class="Figure">
<a name="id481349007"></a><img alt="Budesonide Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7633c9b3-dfb5-446f-a260-e44b6e48afa2&amp;name=a5c63bee-ad0a-4140-ba53-9d7383b41e36-01.jpg">
</div>
<p>Budesonide, USP is a white to almost white crystalline powder that is freely soluble in methylene chloride, sparingly soluble in alcohol and practically insoluble in water. Its partition coefficient between octanol and water at pH 5 is 1.6 x 10 ionic strength 0.01.
                            <span class="Sup">3</span></p>
<p>Each capsule for oral administration contains 3 mg of micronized budesonide with the following inactive ingredients: acetyltributyl citrate, colloidal silicon dioxide, crospovidone, dimethicone, ethylcellulose, FD&amp;C Red No. 40 Aluminum Lake, gelatin, lactose monohydrate, magnesium stearate, methacrylic acid copolymer type C, polysorbate 80, sodium hydroxide, sodium lauryl sulfate, talc, titanium dioxide and triethyl citrate.</p>
<p>The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, Propylene Glycol and shellac glaze.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_d172253c-3cbc-47a7-ab8d-2c1903daf597"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_28afff1f-4a49-4dd9-97c6-02491f0cffdf"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Budesonide has a high topical glucocorticosteroid (GCS) activity and a substantial first pass elimination. The formulation contains granules which are coated to protect dissolution in gastric juice, but which dissolve at pH greater than 5.5, i.e., normally when the granules reach the duodenum. Thereafter, a matrix of ethylcellulose with budesonide controls the release of the drug into the intestinal lumen in a time-dependent manner.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_b47d64dc-f972-48d1-80dd-fc00b649e77c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Budesonide has a high glucocorticoid effect and a weak mineralocorticoid effect, and the affinity of budesonide to GCS receptors, which reflects the intrinsic potency of the drug, is about 200-fold that of cortisol and 15-fold that of prednisolone.</p>
<p>Treatment with systemically active GCS is associated with a suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. Markers, indirect and direct, of this are cortisol levels in plasma or urine and response to ACTH stimulation.</p>
<p>Plasma cortisol suppression was compared following 5 days’ administration of budesonide capsules (enteric coated) and prednisolone in a crossover study in healthy volunteers. The mean decrease in the integrated 0 to 24 hour plasma cortisol concentration was greater (78%) with prednisolone 20 mg per day compared to 45% with budesonide capsules (enteric coated) 9 mg per day.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_cb451699-af19-4691-a06b-a5ff3321acfb"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d2f33b56-04d1-4b42-aafa-99abc767f401"></a><a name="section-11.3.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">The absorption of budesonide capsules (enteric coated) seems to be complete, although C and T are variable. Time to peak concentration varies in individual patients between 30 and 600 minutes. Following oral administration of 9 mg of budesonide in healthy subjects, a peak plasma concentration of approximately 5 nmol/L is observed and the area under the plasma concentration time curve is approximately 30 nmol•hr/L. The systemic availability after a single dose is higher in patients with Crohn's disease compared to healthy volunteers, (21% vs 9%) but approaches that in healthy volunteers after repeated dosing.
                                            <span class="Sub">max</span><span class="Sub">max</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a3919ddb-6f05-4eee-8344-acfcacc3382f"></a><a name="section-11.3.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The mean volume of distribution (V ) of budesonide varies between 2.2 and 3.9 L/kg in healthy subjects and in patients. Plasma protein binding is estimated to be 85 to 90% in the concentration range 1 to 230 nmol/L, independent of gender. The erythrocyte/plasma partition ratio at clinically relevant concentrations is about 0.8.
                                            <span class="Sub">ss</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a8b757d2-3e9d-44bc-a39a-712c4c67be04"></a><a name="section-11.3.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Following absorption, budesonide is subject to high first pass metabolism (80% to 90%). experiments in human liver microsomes demonstrate that budesonide is rapidly and extensively biotransformed, mainly by CYP3A4, to its two major metabolites, 6β-hydroxy budesonide and 16α-hydroxy prednisolone. The glucocorticoid activity of these metabolites is negligible (less than 1/100) in relation to that of the parent compound.
                                            <span class="Italics">In vitro</span></p>
<p>investigations with intravenous doses in healthy subjects are in agreement with the findings and demonstrate that budesonide has a high plasma clearance, 0.9 to 1.8 L/min. Similarly, high plasma clearance values have been shown in patients with Crohn’s disease. These high plasma clearance values approach the estimated liver blood flow, and, accordingly, suggest that budesonide is a high hepatic clearance drug.
                                            <span class="Italics">In vivo</span><span class="Italics">in vitro</span></p>
<p>The plasma elimination half-life, t , after administration of intravenous doses ranges between 2 and 3.6 hours, and does not differ between healthy adults and patients with Crohn’s disease.
                                            <span class="Sub">1/2</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_35361657-b038-4b7f-9f92-bd6004a7045a"></a><a name="section-11.3.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Budesonide is excreted in urine and feces in the form of metabolites. After oral as well as intravenous administration of micronized [ H]-budesonide, approximately 60% of the recovered radioactivity is found in urine. The major metabolites, including 6β-hydroxy budesonide and 16α-hydroxy prednisolone, are mainly renally excreted, intact or in conjugated forms. No unchanged budesonide is detected in urine.
                                            <span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a2822c77-29ee-4916-bf26-97d520b87d38"></a><a name="section-11.3.5"></a><p></p>
<h3>Special Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_10fa244f-95aa-4711-b13c-8b7ba9bd1283"></a><a name="section-11.3.5.1"></a><p></p>
<h4>Gender</h4>
<p class="First">No significant pharmacokinetic differences have been identified due to gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0dbd6997-fde1-4f1a-9c95-5d76f27b9baa"></a><a name="section-11.3.5.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h4>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span>, systemic availability of orally administered budesonide correlates with disease severity and is, on average, 2.5-fold higher compared with healthy controls. Patients with mild liver disease are minimally affected. Patients with severe liver dysfunction were not studied. Absorption parameters are not altered, and for the intravenous dose, no significant differences in CL or V are observed.
                                                    <span class="Sub">ss</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_37c0b266-e3aa-4160-a2b2-2fb72674fc32"></a><a name="section-11.3.5.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h4>
<p class="First">The pharmacokinetics of budesonide in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has not been studied. Intact budesonide is not renally excreted, but metabolites are to a large extent, and might therefore reach higher levels in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. However, these metabolites have negligible corticosteroid activity as compared with budesonide (less than 1/100).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c208a3ec-126c-4a73-87f6-85bab3e48bb6"></a><a name="section-11.3.6"></a><p></p>
<h3>Drug-Drug Interactions</h3>
<p class="First">Budesonide is metabolized via CYP3A4. Potent inhibitors of CYP3A4 can increase the plasma levels of budesonide several-fold. Co-administration of ketoconazole results in an 8-fold increase in AUC of budesonide, compared to budesonide alone. Grapefruit juice, an inhibitor of gut mucosal CYP3A, approximately doubles the systemic exposure of oral budesonide. Conversely, induction of CYP3A4 can result in the lowering of budesonide plasma levels.</p>
<p>Oral contraceptives containing ethinyl estradiol, which are also metabolized by CYP3A4, do not affect the pharmacokinetics of budesonide. Budesonide does not affect the plasma levels of oral contraceptives (i.e., ethinyl estradiol) [ ].
                                            <span class="Italics">see
                                                <a href="#ID_2f34ddac-35bd-4586-a9e0-d642b0993690">Drug Interactions (7)</a></span></p>
<p>Since the dissolution of the coating of budesonide capsules (enteric coated) is pH dependent (dissolves at pH greater than 5.5), the release properties and uptake of the compound may be altered after treatment with drugs that change the gastrointestinal pH. However, the gastric acid inhibitory drug omeprazole, 20 mg once daily does not affect the absorption or pharmacokinetics of budesonide capsules (enteric coated). When an uncoated oral formulation of budesonide is co-administered with a daily dose of cimetidine 1 g, a slight increase in the budesonide peak plasma concentration and rate of absorption occurs, resulting in significant cortisol suppression.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e293d8c9-5afe-486a-aa95-b3a24ef6cdb2"></a><a name="section-11.3.6.1"></a><p></p>
<h4>Food Effects</h4>
<p class="First">A mean delay in time to peak concentration of 2.5 hours is observed with the intake of a high-fat meal, with no significant differences in AUC.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_c38e04f4-e31b-4372-ad3f-e5beeb9f0080"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_5fda71ba-fa1f-41ce-a6db-3f4414dbee0a"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies with budesonide were conducted in rats and mice. In a 2-year study in Sprague-Dawley rats, budesonide caused a statistically significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> in male rats at an oral dose of 50 mcg/kg (approximately 0.05 times the maximum recommended human dose on a body surface area basis). In addition, there were increased incidences of primary hepatocellular tumors in male rats at 25 mcg/kg (approximately 0.023 times the maximum recommended human dose on a body surface area basis) and above. No tumorigenicity was seen in female rats at oral doses up to 50 mcg/kg (approximately 0.05 times the maximum recommended human dose on a body surface area basis). In an additional 2-year study in male Sprague-Dawley rats, budesonide caused no <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> at an oral dose of 50 mcg/kg (approximately 0.05 times the maximum recommended human dose on a body surface area basis). However, it caused a statistically significant increase in the incidence of hepatocellular tumors at an oral dose of 50 mcg/kg (approximately 0.05 times the maximum recommended human dose on a body surface area basis). The concurrent reference corticosteroids (prednisolone and triamcinolone acetonide) showed similar findings. In a 91-week study in mice, budesonide caused no treatment-related carcinogenicity at oral doses up to 200 mcg/kg (approximately 0.1 times the maximum recommended human dose on a body surface area basis).</p>
<p>Budesonide was not genotoxic in the Ames test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward gene mutation (TK ) test, the human lymphocyte chromosome aberration test, the sex-linked recessive lethality test, the rat hepatocyte UDS test and the mouse micronucleus test.
                                    <span class="Sup">+/-</span><span class="Italics">Drosophila melanogaster</span></p>
<p>In rats, budesonide had no effect on fertility at subcutaneous doses up to 80 mcg/kg (approximately 0.07 times the maximum recommended human dose on a body surface area basis). However, it caused a decrease in prenatal viability and viability in pups at birth and during lactation, along with a decrease in maternal body-<span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, at subcutaneous doses of 20 mcg/kg (approximately 0.02 times the maximum recommended human dose on a body surface area basis) and above. No such effects were noted at 5 mcg/kg (approximately 0.005 times the maximum recommended human dose on a body surface area basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_9d3770b1-bd89-4794-b6c7-30b1e47b9661"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The safety and efficacy of budesonide capsules (enteric coated)were evaluated in 994 patients with mild to moderate active Crohn’s disease of the ileum and/or ascending colon in five randomized and double-blind studies. The study patients ranged in age from 17 to 85 (mean 35), 40% were male and 97% were white. Of the 651 patients treated with budesonide capsules (enteric coated), 17 (2.6%) were greater than or equal to 65 years of age and none were greater than 74 years of age. The Crohn’s Disease Activity Index (CDAI) was the main clinical assessment used for determining efficacy in these five studies. The CDAI is a validated index based on subjective aspects rated by the patient (frequency of liquid or very soft stools, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> rating and general well-being) and objective observations (number of extraintestinal symptoms, need for antidiarrheal drugs, presence of <span class="product-label-link" type="condition" conceptid="192438" conceptname="Abdominal mass">abdominal mass</span>, body weight and hematocrit). Clinical improvement, defined as a CDAI score of less than or equal to 150 assessed after 8 weeks of treatment, was the primary efficacy variable in these five comparative efficacy studies of budesonide capsules (enteric coated). Safety assessments in these studies included monitoring of adverse reactions. A checklist of potential symptoms of hypercorticism was used.</p>
<p>One study (Study 1) compared the safety and efficacy of budesonide capsules (enteric coated) 9 mg daily in the morning to a comparator. At baseline, the median CDAI was 272. Budesonide capsules (enteric coated) 9 mg daily resulted in a significantly higher clinical improvement rate at Week 8 than the comparator. See Table 4.</p>
<table>
<caption><span>Table 4. Clinical Improvement Rates (CDAI less than or equal to 150) After 8 Weeks of Treatment</span></caption>
<col width="12%">
<col width="16%">
<col width="28%">
<col width="18%">
<col width="16%">
<col width="18%">
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>This drug is not approved for the treatment of Crohn’s disease in the United States.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Clinical</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Budesonide Capsules (Enteric Coated)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Comparator</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2"><p class="First"><span class="Bold">Prednisolone</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Study</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">9 mg Daily</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">4.5 mg Twice Daily</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">1</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">62/91 (69%)</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">37/83 (45%)</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">31/61 (51%)</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">13/64 (20%)</p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">38/79 (48%)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">41/78 (53%)</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">13/40 (33%)</p></td>
<td class="Lrule Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center"><p class="First">35/58 (60%)</p></td>
<td class="Lrule Rrule" align="center"><p class="First">25/60 (42%)</p></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule"></td>
<td class="Lrule Rrule" align="center"><p class="First">35/58 (60%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45/86 (52%)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">56/85 (65%)</p></td>
</tr>
</tbody>
</table>
<p>Two placebo-controlled clinical trials (Studies 2 and 3) were conducted. Study 2 involved 258 patients and tested the effects of graded doses of budesonide capsules (enteric coated) (1.5 mg twice daily, 4.5 mg twice daily, or 7.5 mg twice daily) versus placebo. At baseline, the median CDAI was 290. The 3 mg per day dose level (data not shown) could not be differentiated from placebo. The 9 mg per day arm was statistically different from placebo (Table 4), while no additional benefit was seen when the daily budesonide capsule (enteric coated) dose was increased to 15 mg per day (data not shown). In Study 3, the median CDAI at baseline was 263. Neither 9 mg daily nor 4.5 mg twice daily budesonide capsule (enteric coated) dose levels was statistically different from placebo (Table 4).</p>
<p>Two clinical trials (Studies 4 and 5) compared budesonide capsules (enteric coated) with oral prednisolone (initial dose 40 mg per day). At baseline, the median CDAI was 277. Equal clinical improvement rates (60%) were seen in the budesonide capsules (enteric coated) 9 mg daily and the prednisolone groups in Study 4. In Study 5, 13% fewer patients in the budesonide capsules (enteric coated) group experienced clinical improvement than in the prednisolone group (no statistical difference) (Table 4).</p>
<p>The proportion of patients with normal plasma cortisol values (greater than 150 nmol/L) was significantly higher in the budesonide capsule (enteric coated) groups in both trials (60% to 66%) than in the prednisolone groups (26% to 28%) at Week 8.</p>
<p>The efficacy and safety of budesonide capsules (enteric coated) for maintenance of clinical remission were evaluated in four double-blind, placebo-controlled, 12-month trials in which 380 patients were randomized and treated once daily with 3 mg or 6 mg budesonide capsules (enteric coated) or placebo. Patients ranged in age from 18 to 73 (mean 37) years. Sixty percent of the patients were female and 99% were Caucasian. The mean CDAI at entry was 96. Among the four clinical trials, approximately 75% of the patients enrolled had exclusively ileal disease. Colonoscopy was not performed following treatment. Budesonide capsules (enteric coated) 6 mg per day prolonged the time to relapse, defined as an increase in CDAI of at least 60 units to a total score greater than 150 or withdrawal due to disease deterioration. The median time to relapse in the pooled population of the four studies was 154 days for patients taking placebo, and 268 days for patients taking budesonide capsules (enteric coated) 6 mg per day. Budesonide capsules (enteric coated) 6 mg per day reduced the proportion of patients with loss of symptom control relative to placebo in the pooled population for the four studies at 3 months (28% vs. 45% for placebo).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_ad21a96f-f47a-4c40-bff1-e2d35091424d"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:68151-4374-0 in a PACKAGE of 1 CAPSULES</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_c6958586-a5ac-4b3c-bbe6-f854bc4f0284"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">“See FDA-Approved Patient Labeling ( )?
                            <a href="#ID_989044e4-27e4-43b8-9e4a-6918bf8ce4a0">Patient Information</a></p>
<p>Patients being treated with budesonide capsules (enteric coated) should receive the following information and instructions. This information is intended to aid the patient in the safe and effective use of the medication. It is not a disclosure of all possible adverse or intended effects. For proper use of budesonide capsules (enteric coated) and to attain maximum improvement, the patient should read and follow the accompanying
                            <span class="Italics">FDA-Approved Patient Labeling.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_50da2007-b5ab-442c-8e2c-b3aca41241b0"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Hypercorticism and Adrenal Suppression</h2>
<p class="First">Patients should be advised that budesonide capsules (enteric coated) may cause systemic glucocorticosteroid effects of hypercorticism and adrenal suppression. Patients should taper slowly from systemic glucocorticosteroids if transferring to budesonide capsules (enteric coated) [ ].
                                    <span class="Italics">see and
                                        <a href="#ID_ebcddafe-38b0-4f25-b37d-eb96b86d81cc">Warnings and Precautions (5.1)</a><a href="#ID_c73ecdc3-be45-4c39-82d0-2620835785b0">(5.2)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16f7822b-a366-4fc9-a47c-65208c4088de"></a><a name="section-15.2"></a><p></p>
<h2>17.2	<span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">Immunosuppression</span></h2>
<p class="First">Patients who are on immunosuppressant doses of glucocorticosteroids should be warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> and, if exposed, to consult their physician without delay. Patients should be informed of potential worsening of existing <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>, fungal, bacterial, viral or parasitic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [ ].
                                    <span class="Italics">see
                                        <a href="#ID_379c624d-3894-486e-8301-31cf2e6028ce">Warnings and Precautions (5.3)</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f5a8ad91-5340-4c81-b350-6f3b4db61ac4"></a><a name="section-15.3"></a><p></p>
<h2>17.3	How to Take Budesonide Capsules (enteric coated)</h2>
<p class="First">Budesonide capsules (enteric coated) should be swallowed whole and NOT CHEWED OR BROKEN. Patients should be advised to avoid the consumption of grapefruit juice for the duration of their budesonide capsules (enteric coated) therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_989044e4-27e4-43b8-9e4a-6918bf8ce4a0"></a><a name="section-16"></a><p></p>
<h1>     </h1>
<p class="First"><span class="Bold">PATIENT INFORMATION LEAFLET BUDESONIDE CAPSULES (enteric coated) (bue des' oh nide) 3 mg
                                <br><br><br></span></p>
<p>Read the Patient Information that comes with budesonide capsules (enteric coated) before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What are budesonide capsules (enteric coated)?</span></p>
<p>Budesonide capsules (enteric coated) are a prescription glucocorticosteroid medicine used in people with mild to moderate Crohn’s disease that affects part of the small intestine (ileum) and part of the large intestine (ascending colon):</p>
<dl>
<dt>•</dt>
<dd>to treat active Crohn’s disease
                                </dd>
<dt>•</dt>
<dd>to help keep symptoms from coming back for up to 3 months.
                                </dd>
</dl>
<p>It is not known if budesonide capsules (enteric coated) are safe and effective in children.</p>
<p><span class="Bold">Who should not take budesonide capsules (enteric coated)?</span></p>
<p><span class="Bold">Do not take budesonide capsules (enteric coated)</span><span class="Bold">if:</span></p>
<dl>
<dt>•</dt>
<dd>you are allergic to budesonide or any of the ingredients in budesonide capsules (enteric coated). See the end of this leaflet for a complete list of ingredients in budesonide capsules (enteric coated).
                                </dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking budesonide capsules (enteric coated)?</span></p>
<p>:
                            <span class="Bold">Before you take budesonide capsules (enteric coated)</span><span class="Bold">tell your healthcare provider if you</span></p>
<dl>
<dt>•</dt>
<dd>have liver problems
                                </dd>
<dt>•</dt>
<dd>are planning to have surgery
                                </dd>
<dt>•</dt>
<dd>have chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> or have recently been near anyone with chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>
                                </dd>
<dt>•</dt>
<dd>have or had a family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span> or <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>
                                </dd>
<dt>•</dt>
<dd>have or had <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>
                                </dd>
<dt>•</dt>
<dd>have high blood pressure (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>)
                                </dd>
<dt>•</dt>
<dd>have decreased bone mineral density (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>)
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span>
                                </dd>
<dt>•</dt>
<dd>any other medical condition
                                </dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if budesonide capsules (enteric coated) may harm your unborn baby.
                                </dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. Budesonide can pass into breast milk and may harm your baby. You and your healthcare provider should decide if you will take budesonide capsules (enteric coated) or breastfeed. You should not do both.
                                </dd>
</dl>
<p>including prescription and non-prescription medicines, vitamins, and herbal supplements. Budesonide capsules (enteric coated) and other medicines may affect each other causing side effects.
                            <span class="Bold">Tell your healthcare provider about all the medicines you take,</span></p>
<p>Especially tell your healthcare provider if you take:</p>
<dl>
<dt>•</dt>
<dd>a glucocorticosteroid medicine
                                </dd>
<dt>•</dt>
<dd>medicines that suppress your immune system (immunosuppressant)
                                </dd>
<dt>•</dt>
<dd>ketoconazale or other medicines that affect how your liver works.
                                </dd>
</dl>
<p>Ask your healthcare provider or pharmacist if you are not sure if your medicine is one listed above.</p>
<p><span class="Bold">How should I take budesonide capsules (enteric coated)?</span></p>
<dl>
<dt>•</dt>
<dd>Take budesonide capsules (enteric coated) exactly as your healthcare provider tells you.
                                </dd>
<dt>•</dt>
<dd>Your healthcare provider will tell you how many budesonide capsules (enteric coated) to take. Your healthcare provider may change your dose if needed.
                                </dd>
<dt>•</dt>
<dd>Take budesonide capsules (enteric coated) in the morning.
                                </dd>
<dt>•</dt>
<dd>Take budesonide capsules (enteric coated) whole. Do not chew or crush budesonide capsules (enteric coated) before swallowing.
                                </dd>
</dl>
<p><span class="Bold">What should I avoid while taking budesonide capsules (enteric coated)?</span></p>
<dl>
<dt>•</dt>
<dd>Do not eat grapefruit or drink grapefruit juice while taking budesonide capsules (enteric coated). Eating grapefruit or drinking grapefruit juice can increase the level of budesonide in your blood.
                                </dd>
</dl>
<p><span class="Bold">What are the possible side effects of budesonide capsules (enteric coated)?</span></p>
<dl>
<dt>•</dt>
<dd>Long-time use of budesonide capsules (enteric coated) can cause you to have too much glucocorticosteroid medicine in your blood. Tell your healthcare provider if you have any of the following signs and symptoms of hypercorticism:
                                <span class="Bold">Effects of having too much glucocorticosteroid medicine in your blood (hypercorticism).</span><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>
                                        </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> easily
                                        </dd>
<dt>o</dt>
<dd>rounding of your face (<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>)
                                        </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4144411" conceptname="Swollen ankle">ankle swelling</span>
                                        </dd>
<dt>o</dt>
<dd>thicker or more hair on your body and face
                                        </dd>
<dt>o</dt>
<dd>a fatty pad or hump between your shoulders (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>)
                                        </dd>
<dt>o</dt>
<dd>pink or purple stretch marks on the skin of your abdomen, thighs, breasts and arms
                                        </dd>
</dl>
</dd>
<dt>•</dt>
<dd>When budesonide capsules (enteric coated) are taken for a long period of time (chronic use), adrenal suppression can happen. This is a condition in which the adrenal glands do not make enough steroid hormones. Symptoms of adrenal suppression include: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>. Tell your healthcare provider if you are under stress or have any symptoms of adrenal suppression during treatment with budesonide capsules (enteric coated).
                                <span class="Bold">Adrenal suppression.</span>
</dd>
<dt>•</dt>
<dd>Budesonide capsules (enteric coated) weaken your immune system. Taking medicines that weaken your immune system makes you more likely to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Avoid contact with people who have contagious diseases such as chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, while taking budesonide capsules (enteric coated). Tell your healthcare provider about any signs or symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> during treatment with budesonide capsules (enteric coated), including:
                                <span class="Bold">Immune system effects and a higher chance of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</span><br><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
                                        </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>
                                        </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>
                                        </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>
                                        </dd>
<dt>o</dt>
<dd>feeling tired
                                        </dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
                                        </dd>
</dl>
</dd>
<dt>•</dt>
<dd>If you take certain other glucocorticosteroid medicines to treat allergies, switching to budesonide capsules (enteric coated) may cause your allergies to come back. These allergies may include <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span> (a skin disease) or <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> inside your nose). Tell your healthcare provider if any of your allergies become worse while taking budesonide capsules (enteric coated).
                                <span class="Bold">Worsening of allergies.</span>
</dd>
</dl>
<p>The most common side effects of budesonide capsules (enteric coated) include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in your air passages (<span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory infection</span>)
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>
                                </dd>
<dt>•</dt>
<dd>excessive stomach or intestinal gas
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>
                                </dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of budesonide capsules (enteric coated). For more information, ask your healthcare provider or pharmacist.</p>
<p><span class="Bold">Call your healthcare provider for medical advice about side effects. You may report side effects to Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
<p><span class="Bold">How should I store budesonide capsules (enteric coated)?</span></p>
<dl>
<dt>•</dt>
<dd>Store budesonide capsules (enteric coated) at 20° to 25°C (68° to 77°F).
                                </dd>
<dt>•</dt>
<dd>Keep budesonide capsules (enteric coated) in a tightly closed container.
                                </dd>
</dl>
<p><span class="Bold">Keep budesonide capsules (enteric coated)</span><span class="Bold">and all medicines out of reach from children.</span></p>
<p><span class="Bold">General information about budesonide capsules (enteric coated).</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use budesonide capsules (enteric coated) for a condition for which it was not prescribed. Do not give budesonide capsules (enteric coated) to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information leaflet summarizes the most important information about budesonide capsules (enteric coated). If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about budesonide capsules (enteric coated) that is written for health professionals.</p>
<p>For more information call Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX).</p>
<p><span class="Bold">What are the ingredients in budesonide capsules (enteric coated)?</span></p>
<p>Active ingredient: budesonide, USP</p>
<p>Inactive ingredients: acetyltributyl citrate, colloidal silicon dioxide, crospovidone, dimethicone, ethylcellulose, FD&amp;C Red No. 40 Aluminum Lake, gelatin, lactose monohydrate, magnesium stearate, methacrylic acid copolymer type C, polysorbate 80, sodium hydroxide, sodium lauryl sulfate, talc, titanium dioxide and triethyl citrate.</p>
<p>The imprinting ink contains the following: black iron oxide, D&amp;C Yellow No. 10 Aluminum Lake, FD&amp;C Blue No. 1 Aluminum Lake, FD&amp;C Blue No. 2 Aluminum Lake, FD&amp;C Red No. 40 Aluminum Lake, Propylene Glycol and shellac glaze.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Morgantown, WV  26505  U.S.A.
                            <span class="Bold">Mylan Pharmaceuticals Inc.
                                <br></span></p>
<p>REVISED FEBRUARY 2014 BUDE:R2ppt
                            <br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_68f408e5-cbc7-4405-9935-f9f5e011193c"></a><a name="section-17"></a><p></p>
<h1>Budsonide</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7633c9b3-dfb5-446f-a260-e44b6e48afa2&amp;name=68151-4374.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BUDESONIDE 		
					</strong><br><span class="contentTableReg">budesonide capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-4374(NDC:0378-7155)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BUDESONIDE</strong> (BUDESONIDE) </td>
<td class="formItem">BUDESONIDE</td>
<td class="formItem">3 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETYLTRIBUTYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>DIMETHICONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ETHYLCELLULOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (red opaque) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">18mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MYLAN;7155</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-4374-0</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090410</td>
<td class="formItem">08/23/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-4374)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>4e0daaa9-b926-4033-93c4-47fefd919ed3</div>
<div>Set id: 7633c9b3-dfb5-446f-a260-e44b6e48afa2</div>
<div>Version: 2</div>
<div>Effective Time: 20140305</div>
</div>
</div> <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
